Poor planning, patient reluctance, and payer problems hurting gene therapy space
Cell and gene therapies (CGTs) have finally come of age and are making a mark on the regulatory landscape. At...
hurting
Cell and gene therapies (CGTs) have finally come of age and are making a mark on the regulatory landscape. At...
